Pharma BD Deal Intelligence
Myovant and Pfizer announced a US/Canada collaboration to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and relugolix combination tablet in women's health. Myovant received $650M upfront plus $200M regulatory milestones for relugolix combo tablet women's health approvals and tiered sales milestones up to $3.5B+, total deal up to $4.2B. Profits and certain expenses split 50/50 with Myovant booking revenue. Post-close development: in October 2022 Sumitovant Biopharma (Sumitomo Pharma group), which already held a majority stake, agreed to acquire the remaining Myovant shares at $27.00/share ($1.7B; ~$2.9B total company value); the deal completed March 10, 2023, making Myovant a wholly owned Sumitovant subsidiary and delisting it from the NYSE. The Pfizer collaboration was not terminated and continues under Myovant as a Sumitomo subsidiary.
Assessment window: 5yr post-close.